Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 1 Infection
Condition: Herpes Labialis Interventions: Drug: HDIT101 (blinded therapy); Drug: Placebo (blinded therapy); Behavioral: Photo documentation of orolabial herpes lesions; Behavioral: Completion of questionnaires (patient-reported outcomes); Procedure: 28-day swabbing of orolabial region; Procedure: Blood drawin gs Sponsor: Heidelberg ImmunoTherapeutics GmbH Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2020 Category: Research Source Type: clinical trials